Thierry Chardès

ResearcherID ISNI Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Venues

Journal for immunotherapy of cancer

International journal of cancer

Cancers

Cancer science

IRCM Institut de Recherche en Cancérologie de Montpellier

Université de Montpellier - Faculté de Pharmacie (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IRCM Institut de Recherche en Cancérologie de Montpellier Jan 01 2008

France

Research Director, DR1 CNRS, PhD, PharmD

Education History

Université de Montpellier - Faculté de Pharmacie Sep 01 1982 - Sep 30 1987

France

MSC :: Immunology laboratory

Publications

Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Lindsay B Alcaraz, Aude Mallavialle, Caroline Mollevi, Florence Boissière-Michot, Hanane Mansouri, Joelle Simony-Lafontaine, Valérie Laurent-Matha, Thierry Chardès, William Jacot, Andrei Turtoi, Pascal Roger, Séverine Guiu, Emmanuelle Liaudet-Coopman
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. International journal of cancer (2022)
Christel Larbouret, Laurent Gros, André Pèlegrin, Thierry Chardès
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. Cancers 13 (18) (2021)
Christel Larbouret, Marie-Alix Poul, Thierry Chardès
[Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]. Medecine sciences : M/S 35 (12) (2020)
Romain Lanotte, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Astrid Musnier, Pierre Martineau, André Pèlegrin, Thierry Chardès
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking. Cancer science 111 (7) (2020)
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Carla Sampaio, Christel Larbouret, Romain Lanotte, Marie-Alix Poul, Jean-Marc Barret, Jean-François Prost, André Pèlegrin, Thierry Chardès
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell communication and signaling : CCS 17 (1) (2019)
Laura Bourillon, Céline Bourgier, Nadège Gaborit, Véronique Garambois, Eva Llès, Alexandre Zampieri, Charline Ogier, Marta Jarlier, Nina Radosevic-Robin, Béatrice Orsetti, Hélène Delpech, Charles Theillet, Pierre-Emmanuel Colombo, David Azria, André Pèlegrin, Christel Larbouret, Thierry Chardès
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. International journal of cancer 145 (7) (2019)

Thierry Chardès.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thierry Chardès